Estimate spontaneous passage rates by stone size and location, treatment options, prevention strategies, and 24-hour urine interpretation for kidney stones.
The Kidney Stone Calculator estimates spontaneous passage probability, expected passage time, treatment direction, and prevention steps based on stone size, location, and composition. Stone management often starts with the question of whether observation and medical expulsive therapy are reasonable or whether procedural treatment is more likely to be needed.
Stone size and location matter most in the acute setting: small distal ureteral stones pass more often than larger or more proximal stones. This calculator maps those inputs to a practical management summary and can also interpret 24-hour urine metabolic data when prevention planning is needed.
For recurrent stone formers, the page can also highlight common prevention themes such as fluid intake, sodium reduction, citrate, and composition-specific diet changes.
Stone size, location, and composition can change the expected course quite a bit, so a quick estimate is useful when deciding whether observation is reasonable or whether earlier urologic treatment should be discussed. The same page also helps frame prevention work after the acute episode passes.
Spontaneous passage rates derived from meta-analyses: distal ureter <4mm: 76-95%, 4-6mm: 60%, >6mm: 35%. Proximal ureter rates are 20-30% lower. Medical expulsive therapy (tamsulosin) increases passage rates by ~30% for stones 5-10mm.
Result: 60% passage rate, expected 2-4 weeks with MET
A 5mm distal ureteral calcium oxalate stone has approximately 60% chance of spontaneous passage. Medical expulsive therapy with tamsulosin 0.4 mg daily is often discussed alongside hydration and pain-control planning. NSAIDs (ketorolac, ibuprofen) for pain control.
**Calcium Oxalate (70-80%)**: The most common stone type, often with calcium phosphate core. Risk factors include hypercalciuria, hyperoxaluria, hypocitraturia, and low urine volume. Dietary management focuses on adequate calcium intake (1000-1200 mg/day — paradoxically, adequate calcium binds dietary oxalate in the gut), reduced sodium and animal protein, increased citrate, and avoidance of high-oxalate foods (spinach, nuts, chocolate). Thiazide diuretics reduce urinary calcium; potassium citrate increases urinary citrate.
**Uric Acid (5-10%)**: The only dissolution-eligible stone. Form in acidic urine (pH < 5.5) and are radiolucent on X-ray. Management: alkalinize urine to pH 6.0-6.5 with potassium citrate (20-30 mEq TID), increase fluids, reduce purine-rich foods. Allopurinol for hyperuricemia. Complete dissolution may take 2-6 months.
**Struvite (5-15%)**: Caused by urease-producing bacteria that split urea into ammonia, raising urine pH and creating magnesium ammonium phosphate crystals. Can form large "staghorn" calculi filling the renal pelvis. Treatment requires surgical removal plus targeted antibiotics. Acetohydroxamic acid (AHA) inhibits urease but has significant side effects.
**Cystine (1-2%)**: Autosomal recessive cystinuria causing excessive urinary cystine. Requires lifelong management: very high fluid intake (>3L/day, including nighttime waking), urine alkalinization to pH 7.0-7.5, sodium restriction, and potentially tiopronin or D-penicillamine for refractory cases.
The three main surgical options for kidney stones differ in their indications and effectiveness:
**ESWL** (Extracorporeal Shock Wave Lithotripsy): Non-invasive, outpatient. Best for renal stones ≤20mm and proximal ureteral stones. Stone-free rates 50-70%. Less effective for lower pole stones, hard stones (calcium oxalate monohydrate, cystine), obese patients, and stones >15mm. No incisions required.
**Ureteroscopy (URS)**: Flexible or semi-rigid scope with laser lithotripsy. Stone-free rates 80-95% for ureteral stones, 70-85% for renal stones. Can treat stones in any location. Requires anesthesia and possible stent placement. Gold standard for mid/distal ureteral stones.
**PCNL** (Percutaneous Nephrolithotomy): Most invasive but most effective for large renal stones (>20mm). Stone-free rates 85-95%. Requires percutaneous renal access, hospitalization, and carries higher complication risk. Indicated for staghorn calculi and large stone burdens.
Last updated:
This worksheet applies published stone-size and stone-location passage ranges, plus common metabolic-prevention themes, to summarize acute and preventive kidney-stone context. It is a planning aid, not a urology treatment order or an emergency pathway.
Stones ≤4mm in the distal ureter pass spontaneously 76-95% of the time. Stones 5-6mm have about 60% passage rates with medical expulsive therapy. Stones >6mm in the ureter and >10mm in the kidney typically require intervention.
For stones 5-10 mm, tamsulosin (an alpha-blocker that relaxes ureteral smooth muscle) can improve passage odds and shorten time to passage. For stones <5 mm, the benefit is less clear, and the best evidence suggests the effect is concentrated in distal ureteral stones.
During acute colic, moderate hydration is recommended — excessive fluid loading can increase ureteral pressure and pain. For prevention, target 2.5-3L of fluid daily (enough to produce >2L of urine). Water is best; lemonade provides citrate; avoid sugar-sweetened beverages.
Non-contrast CT is the gold standard with 95-98% sensitivity. Ultrasound is preferred for pregnancy and pediatrics. CT also detects alternative diagnoses. KUB X-ray can follow known radiopaque stones but misses uric acid and small stones.
Seek emergency care for: fever with stone symptoms (infected obstructing stone is a urologic emergency), inability to keep fluids down, uncontrolled pain despite oral medications, a single kidney, or no urine output. Infected obstruction requires emergency ureteral stent or nephrostomy.
Yes — uric acid stones are the only common stone type that can be dissolved medically. Alkalinizing urine to pH 6.0-6.5 with potassium citrate dissolves existing stones over weeks to months and prevents new ones. This can be a useful option when urine alkalinization is appropriate.